of the metallacages to tumor cells, the bioconjugation of exo-functionalized self-assembled Pd2L 4 cages to peptides following two different approaches is reported for the first time. The obtained bioconjugates were analyzed and identified by high-resolution mass spectrometry.
defined internal cavities and relatively facile pre-or post-self-assembly functionalization. 8 These properties augment the modularity of the directional bonding design strategy to provide structures with unprecedented fine-tuning possibilities, spatially and electronically. In spite of the numerous advantages of SCCs, these systems have been the least-explored of the supramolecular material categories for biomedical applications, both as drug delivery systems and as anticancer agents.
A specific and attractive area of SCCs is the self-assembly of M2L4 (M =metal, L = ligand) metallacages, 9 which can enclose a wide range of small molecules within their cavity, such as ions [10] [11] [12] [13] [14] and neutral molecules. [15] [16] [17] [18] [19] [20] [21] In addition, the properties of the M2L4 coordination cages can be optimized by functionalization of the ligand framework with the aim to target molecular system to a specific cell/tissue type or to enhance detection. Recently, we investigated fluorescent Pd2L4 cages (with L being exofunctionalized bipyridyl ligands) as drug delivery systems for cisplatin, which proved to be active in cancer cells, while showing low ex vivo toxicity in healthy rat liver tissue. 15 The obtained Pd(II) metallacages showed fluorescence properties due to the used ligand system. Similarly, exo-functionalized cages with naphthalene or anthracene groups, or featuring Ru (II) pyridine complexes, were studied with the aim to image their fate in cells via fluorescence microscopy. 22, 23 Selective accumulation of metallacages in tumors has been hypothesized to occur via the enhanced permeability and retention (EPR) effect, 24 which has been widely used in cancer therapy for delivery via passive targeting. In fact, the EPR effect has been predominantly shown to be involved in the passive targeting of drugs with a molecular weight of more than 40 kDa and for low molecular weight drugs presented in drug-carriers such as polymeric conjugates, liposomes, polymeric nanoparticles, and micellar systems to solid tumors. 25 However, for supramolecular metallacages, with molecular weight of ca.
2-3 KDa, the EPR effect is not likely to influence their delivery. Therefore, it can be assumed that successful conjugation of cellspecific ligands to the cage, including tumor-targeting peptides (TTPs) that are specific for tumor related surface markers, such as membrane receptors, 4, 26 could improve target specificity and efficacy. However, so far this concept has never been explored, and only Fujita et al. have been published on the non-covalent peptide coating on self-assembled M12L24 coordination spheres. 27 The synthesis of three Pd2L4 cages and their bioconjugation to a model peptide is reported in this work. To the best of our knowledge this is the first attempt to bioconjugate M2L 4 cages to peptides. The selected cages feature COOH or NH2 groups in exo position for coupling to the peptide by amide bond formation ( Fig. 1, C1a, C1b, C1c ). It is also investigated whether a longer aliphatic linker between the COOH group and the cage favours coupling of the targeting moiety by reducing possible steric hindrance.
It is worth mentioning that we have opted for this classical bioconjugation method instead of the modern click-chemistry approach, since the latter may lead to interference of Cu 2+ ions with the stability of the self-assembled cage. In fact, click chemistry makes often use of copper in the concentration range 50-250 µM or higher, 28 which would be ca. equivalent to the necessary concentration of Pd 2+ precursor and resulting metallacage, therefore, leading to possible ligand exchange reactions.
The bioconjugation was performed using two different approaches: i) direct tethering of the metallacage to the peptide (Approach I); or ii) initial anchoring of the ligand to the peptide, followed by metallacage self-assembly (Approach II) ( Fig. 1) .
Formation of the metallacage-peptide constructs was assessed via high-resolution electrospray mass spectrometry in most cases coupled to high performance liquid chromatography (LC-MS). The obtained results are discussed in relation to the advantages and disadvantages of the reported bioconjugation approaches, and constitute the proof of concept for further studies using peptides selected for targeting properties (e.g. cyclic RGD peptides or affimers).
Synthesis
The rigid bidentatepyridyl ligands L1a-L3a (see as well as of the amine-based ligand L3a and cage C3a were previously reported, 15 while ligand L2a and cage C2a were synthesized for the first time following a similar procedure and characterised by NMR and mass spectrometry ( Table S1 in the Supplementary material). Similar results were obtained when bioconjugating cage C2c, featuring the longer linker between the cage and the COOH group (data not shown). In the case of cage C3a, the activating agent EDC was utilized to promote coupling to the model peptide but most of the peptide appeared to undergo cyclization reactions under these conditions preventing successful bioconjugation.
In general, the obtained results show that it is difficult to both control the number of peptides coupled to the Pd2L4 cage and efficiently separate the mixture of different types of bioconjugated cages using Approach I.
Therefore, Approach II (Fig. 1) Fig. S7 (panels A and C) , and show almost complete conversion of the ligands into the desired products. In fact, L1b
(L1a-peptide) and L2b (L2a-peptide) are obtained, with a yield higher than 90%. The results show no significant difference in yield of coupling reaction using the ligand with longer aliphatic linker. Fig. S7 (panels B and D) (Fig. S7, panels E and F) . Thus, only L1b and L2b were selected to achieve self-assembly of the bioconjugated cages.
Subsequently, the bioconjugated cages C1c or C2c were formed in situ using a 2:1 ratio of L1b or L2b and the Pd 2+ precursor [Pd(NCCH3)4](BF4)2 in DMSO. Representative extracted ion chromatograms and mass spectrum for the bioconjugate cage C2c is reported in Figure 2 . Fig. S8 in the Supplementary material shows the mass spectrum of bioconjugated cage C1c.
The results show that both the bioconjugate ligands L1b and L2b are converted into cage molecules tethered to four peptide units with a yield higher than 95%. 
Conclusions
With the aim of implementing supramolecular metallacages as drug delivery systems, we report the first example of bioconjugation of self-assembled Pd2L4 cages to the model linear peptide Ac-NLEFK-Am. The obtained results open the possibility of efficient bioconjugation of metallacages to peptides which could be extended to targeting moieties such as cyclic RGD peptides or affimers, and possibly also to antibodies. This opportunity is particularly attractive in the case of metallacages encapsulating anticancer drugs (e.g.: cisplatin) in order to efficiently target them to cancer cells. Two approaches of bioconjugation of metallocages to peptides have been attempted, both based on amide bond formation between the carboxylic acid (or amine) serving as exo-functionalized ligand/cage and the amine (or carboxylic acid) groups of the model peptide side chains. So far the best results were achieved with Approach II, where first the coupling of the peptide to the ligands constituting the cages was performed, followed by in-situ reconstitution of the Pd2L4 cages via self-assembly. No major advantages were noticed in the use of a long-linker COOH moiety for bioconjugation in both approaches. Instead, improved bioconjugation efficiency was observed in the case of the exo-functionalization with carboxylic acids compared to amino groups. In the latter case, formation of peptide cyclic by-products prevented efficient bioconjugation under the applied reaction conditions. Nevertheless, NH2 functionalization may still be suitable for bioconjungation of the cages with peptides of different sequences and with antibodies, and will certainly be considered in future studies.
